The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis ; volume:23 ; number:1 ; day:15 ; month:2 ; year:2024 ; pages:1-10 ; date:12.2024
Cardiovascular diabetology ; 23, Heft 1 (15.2.2024), 1-10, 12.2024
- Creator
-
Ali, Muhammad Usman
Mancini, G. B. John
Fitzpatrick-Lewis, Donna
Connelly, Kim A.
O’Meara, Eileen
Zieroth, Shelley
Sherifali, Diana
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-024-02154-w
- URN
-
urn:nbn:de:101:1-2404230832523.639473625151
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ali, Muhammad Usman
- Mancini, G. B. John
- Fitzpatrick-Lewis, Donna
- Connelly, Kim A.
- O’Meara, Eileen
- Zieroth, Shelley
- Sherifali, Diana
- SpringerLink (Online service)
Other Objects (12)
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes